In vitro synergy between linezolid and clarithromycin against

Chapter 6
To the Editor:
Approximately 3% of new tuberculosis (TB) cases worldwide represent multidrug-resistant tuberculosis (MDR-TB) (1) . In these MDR-TB cases, resistance of Mycobacterium tuberculosis against the otherwise effective rifampicin and isoniazid forces clinicians to diverge to other antimicrobial agents. Such treatment options include World Health Organization (WHO) group 5 drugs linezolid and clarithromycin (1) . Linezolid shows excellent efficacy in the treatment of MDR-TB, but its use is often troubled by adverse events (2) (3) (4) . Linezolid has shown in vitro bacteriostatic activity against M. tuberculosis and is also effective at achieving culture conversion in drug resistant patients (5) . In vitro testing revealed that clarithromycin is not very active against M. tuberculosis since the minimal inhibitory concentrations (MIC) are relatively high. Clinical efficacy seems questionable, since MICs, as reported in literature, are significantly higher than achievable serum peak levels in vivo (6) . On the contrary, clarithromycin reaches adequate local concentrations in alveolar cells and in epithelial lining fluid, where most mycobacteria reside (7) . Besides that lower clarithromycin MICs were observed by the Dutch National Mycobacteria Reference Laboratory (Bilthoven, the Netherlands; unpublished data).
Due to the limited number of new treatment options, optimizing existing treatment regimens is a conceivable option. Exploring synergy between tuberculosis drugs might help in improving treatment regimens. A study that investigated several anti-TB drugs, such as isoniazide, rifampin, and/or ethambutol, but not linezolid, revealed in vitro synergistic activity with clarithromycin against M. tuberculosis (8) . In this study, we aim to investigate the possible in vitro synergy between linezolid and clarithromycin in Mycobacterium tuberculosis isolates obtained from multidrug-resistant, resistant, and drug-susceptible TB patients. For the ACM, we used a sterilized Middlebrook 7H10 agar of pH 6.6 supplemented with oleic-acid-dextrose-catalase (both Becton Dickinson and Company, Sparks, MD) and varying concentrations of drugs (9) . The plates were checked for mycobacterial growth after 4, 8, 12, 14, 16, 19 , and 21 days. The plates were analyzed when the growth in the control well without anti-TB drugs was considered sufficient, i.e. when colonies were clearly visible and countable. At this point of time, all wells were checked for growth inhibition. Growth inhibition was defined as less than 90% of the colonies of the control well.
Next to the ACM, the MGIT 960 system with EpiCenter TB eXiST software was used (Becton Dickinson and Company, Sparks, MD) (10) . Each tube contained 0.8 ml of Bactec MGIT drug susceptibility supplement and 100 μl of the appropriate drug solution. Growth was monitored hourly. The tubes were analyzed when growth unit (GU) value of the growth control tube, containing a 1:100 dilution of the inocula, reached 400. Growth inhibition was defined as GU value <100.
The checkerboard method was used to study in vitro synergy between linezolid and clarithromycin (both Sigma Aldrich, St.Louis, MO, USA). Linezolid was added in concentrations between 0 -0.5 μg/mL and clarithromycin with a range of 0 -8 μg/mL as is shown in Figure   1 . We calculated the lowest fractional inhibitory concentration (FIC) to determine synergy as follows: (MIC linezolid, combination / MIC linezolid, alone ) + (MIC clarithromycin, combination / MIC clarithromycin, alone ).
Synergy was defined as a FIC ≤0.5, indifference as FIC >0.5 to 4, and antagonism as FIC >4 (11) .
Of the selected M. tuberculosis isolates (n=24), synergy between clarithromycin and linezolid was determined for 74% by using the MGIT method and in 59% by using the ACM. The In conclusion, we observed synergy between clarithromycin and linezolid both with the MGIT and with the ACM method. This finding is in line with a previous observation that clarithromycin displayed synergy with isoniazide, rifampin, and/or ethambutol in M. tuberculosis (8) .
Although the underlying mechanism is yet to be elucidated, it has been suggested that disorganization or disruption of the outer cell wall layer and the cytoplasmic membrane of the cell envelope by either clarithromycin or linezolid may play a role (8) . This disruption Method (ACM, n=23) . Each cell represents the median result, i.e. growth or no-growth, of all tested isolates. Grey cells indicate growth, white cells indicate >90% less growth than controls. $ in order to calculate the fractional inhibitory concentrations (FIC) 4 μg/mL is used as the MIC clarithromycin, alone . The lowest FIC cell is marked by 'FIC' . For example: the FIC of Figure 1B However, this hypothesis assumes that permeability is normally a limiting factor. Further research studying the underlying mechanism is needed and might also explain the fact that we observed in vitro synergy in the majority, but not all of the isolates. Although the majority of the isolates in this research displayed in vitro synergy when clarithromycin and linezolid were combined, it would be more interesting to determine or predict which isolates display synergy before applying these drugs in treatment regimens. Indeed, checkerboard experiments have not been validated or widely accepted for tailoring treatment in individual cases, and therefore cut-off values for FIC to deviate from the theoretical cut-off value of 1.0 have been employed (11) . Consequently, the number of isolates displaying synergy might be under-or overestimated.
Figure 1 Schematic median checkerboard of Mycobacteria tuberculosis growth inhibition with varying concentrations of clarithromycin and/or linezolid using A. Mycobacteria Growth Indicator Tubes (MGIT, n=23) and B. Absolute Concentration
Previously, we showed that clarithromycin increases linezolid exposure by 44% in MDR-TB patients (12) . 
